Pre-implantation Genetic Screening (PGS) is a genetic test that is commonly performed during IVF treatment to examine embryos for chromosomal abnormalities and gender selection. An embryo biopsy is performed on day 3 to 5 to examine 22 non-sex chromosomes and the sex chromosomes before the embryo transfer.

Women who are over 35, have family history of chromosome abnormalities, have a history of recurrent miscarriages or those who have experienced multiple IVF failures may benefit from the genetic testing. At the same time, PGS is often used for family balance as it tells sex chromosome of embryos. Chromosome abnormalities are one of the main factors that cause recurrent miscarriage, mental retardation and birth defects. As PGS identifies chromosomally normal embryos it improves implantation rates, reduces abortion, increases ongoing pregnancy rate.

It detects gender with 99.99% accuracy and sex chromosome abnormalities such as Klinefelter Syndrome(XXY), Turner’s Syndrome(XO), Triple X Syndrome (XXX), and XYY Syndrome.